GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvalent Inc (NAS:NUVL) » Definitions » Cash Flow from Investing

NUVL (Nuvalent) Cash Flow from Investing : $-459.73 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nuvalent Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2024, Nuvalent spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $340.62 Mil on purchasing investments. It gained $127.71 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it received $0.00 Mil from other investing activities. In all, Nuvalent spent $212.91 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2024.


Nuvalent Cash Flow from Investing Historical Data

The historical data trend for Nuvalent's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvalent Cash Flow from Investing Chart

Nuvalent Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
- - -220.03 -10.67 -143.53

Nuvalent Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.40 -56.26 -206.77 16.21 -212.91

Nuvalent Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Nuvalent's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Nuvalent's Cash Flow from Investing for the quarter that ended in Sep. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-459.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuvalent  (NAS:NUVL) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Nuvalent's purchase of property, plant, equipment for the three months ended in Sep. 2024 was $0.00 Mil. It means Nuvalent spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Nuvalent's sale of property, plant, equipment for the three months ended in Sep. 2024 was $0.00 Mil. It means Nuvalent gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Nuvalent's purchase of business for the three months ended in Sep. 2024 was $0.00 Mil. It means Nuvalent spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Nuvalent's sale of business for the three months ended in Sep. 2024 was $0.00 Mil. It means Nuvalent gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Nuvalent's purchase of investment for the three months ended in Sep. 2024 was $-340.62 Mil. It means Nuvalent spent {stock_data.stock.currency_symbol}}340.62 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Nuvalent's sale of investment for the three months ended in Sep. 2024 was $127.71 Mil. It means Nuvalent gained $127.71 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Nuvalent's net Intangibles purchase and sale for the three months ended in Sep. 2024 was $0.00 Mil. It means Nuvalent paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Nuvalent's cash from discontinued investing activities for the three months ended in Sep. 2024 was 0.00 Mil. It means Nuvalent paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Nuvalent's cash from other investing activities for the three months ended in Sep. 2024 was $0.00 Mil. It means Nuvalent received $0.00 Mil from other investing activities.


Nuvalent Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Nuvalent's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvalent Business Description

Traded in Other Exchanges
N/A
Address
One Broadway, 14th Floor, Cambridge, MA, USA, 02142
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Executives
Alexandra Balcom officer: Chief Financial Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Matthew Shair director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
James Richard Porter director, officer: President and CEO ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Darlene Noci officer: See Remarks ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
James E Flynn director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deborah Ann Miller officer: Chief Legal Officer C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Emily Conley director C/O NUVALENT, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02142
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher Durant Turner officer: Chief Medical Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Deerfield Mgmt L.p. director, 10 percent owner, other: * Director by deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. director, 10 percent owner, other: Director by Deputization 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Michael L. Meyers director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Deerfield Private Design Fund Iv, L.p. director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Robert Bowers Jackson director C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142